Introduction {#sec1-1}
============

Among the selected articles from 1999 to 2012, the prevalence of hypertension was 17%. The prevalence of hypertension among the people above 20 years was 24% and that among the people below 20 years was 5%.\[[@ref1]\] In 32 studies with a sample of 34,714 subjects, the prevalence of hypertension in Iranian diabetic patients was 51% (95% CI: 43%--60%). The prevalence of hypertension was 55% in type I diabetics and 53% in type II diabetic patients.\[[@ref2]\] In Haghdoust study, in 2006, the prevalence of hypertension in 29 studies was 21.9%.\[[@ref3]\]

Today, chronic disease is one of the most important health problems affecting different dimensions of physical, psychological, economic, social, and quality of life of patients.\[[@ref4][@ref5][@ref6][@ref7][@ref8][@ref9]\] Hypertension is a common chronic disease that underlies several diseases such as heart attack, brain attack, and advanced kidney disease,\[[@ref10][@ref11][@ref12][@ref13][@ref14][@ref15][@ref16][@ref17]\] which is defined as systolic blood pressure above 140 mmHg and diastolic blood pressure above 90 mmHg.\[[@ref12]\] As a global problem, it is a common asymptomatic disease, often called a silent killer.\[[@ref18]\] According to the World Health Organization, high blood pressure after smoking has been introduced as the second leading cause of death in developing countries and is the third most common cause of noncommunicable diseases. This disease has different prevalence in different societies and the prevalence ranges from 10% to more than 60% in different countries.\[[@ref19][@ref20]\] It has also been estimated that blood pressure has been responsible for 4.5% of the global burden of diseases.\[[@ref21][@ref22][@ref23][@ref24]\]

End-stage renal disease (ESRD) is the severe type of chronic kidney disease, which is the final stage of an irreversible progressive renal disorder. In this disease, the body\'s ability to maintain the balance between fluid and electrolyte disappears and leads to uremia or asthenia.\[[@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31]\] In fact, when more than 95% of the kidney tissue is destroyed for various reasons, the accumulation of toxins in the body increases considerably and life-threatening complications force the person to undergo Renal replacement therapies forever.\[[@ref32][@ref33]\] The population of patients with kidney failure in Iran is 320,000; 49% of them use renal transplantation therapy, 48% of them use the hemodialysis method, and 3% of them use the peritoneal dialysis method.\[[@ref34]\] This disease can lead to death if the patient does not undergo dialysis or kidney transplantation.\[[@ref25][@ref26][@ref27][@ref35][@ref36][@ref37]\]

In 1990, renal failure was considered as the 27^th^ mortality factor in the world, and reached the 18^th^ rank in 2010.\[[@ref38]\] According to the Centers for Disease Control and Prevention, in 2014, more than 20% of people with serious hypertension suffered from chronic kidney disease and were at risk for ESRD.\[[@ref39]\] On the other hand, about 75%--80% of patients with ESRD have high blood pressure.\[[@ref40]\] In all developed countries and in many developing countries, diabetes and hypertension are considered as the main cause of chronic kidney disease.\[[@ref23][@ref36][@ref41][@ref42][@ref43][@ref44][@ref45][@ref46][@ref47][@ref48]\]

Considering that published articles about the prevalence of hypertension in renal patients in Iran reported varied incidence of 9%--86% for the prevalence of high blood pressure, the need for a meta-analysis seemed necessary.

Materials and Methods {#sec1-2}
=====================

Study protocol {#sec2-1}
--------------

This study is a systematic review and meta-analysis study that the prevalence of hypertension in Iranian renal patients. This study was conducted on the basis of the PRISMA^1^ statement that is concerned with systematic review and meta-analysis studies.\[[@ref49]\] Based on this protocol, all stages of the research methodology such as search, selection of studies and qualitative assessment of studies, and data extraction from the studies were conducted by two researchers independently. If there was a difference in the report of the researchers, the third researcher investigated and resolved the dispute.

Search strategy {#sec2-2}
---------------

This study is a meta-analysis that investigates the prevalence of hypertension in renal patients. The findings of this study were based on studies conducted in Iran. We searched national databases including IranMedex, SID, Magiran, IranDoc and Medlib, and international databases including ScienceDirect, PubMed, Scopus, Cochrane, Embase, Web of Science, and Medline. The mechanism for searching articles mainly based on the systematic search of related Persian keywords and their English equivalents ("Iran," "Meta-analysis," "Kidney disease," "Renal disease," "Hypertension") was carried out independently by two researchers. For the final analysis, keywords were also searched in the Google Scholar search engine without time limit until 2017. It should be noted that the keywords were also searched together using (OR/AND) operators.

Study selection {#sec2-3}
---------------

First, all articles related to this subject in Iran were collected and a list of abstracts was prepared after the search was completed. This task was done independently by two researchers. Then, the articles with duplicate titles were excluded. Subsequently, the abstracts of articles were reviewed to find appropriate studies. Regarding international databases, the process was similar to that of national databases.

In the first stage of the search, 732 articles were found, and after reviewing the titles of articles, 285 overlapping articles were removed. Among the remaining 447 papers, 229 articles were excluded from the exit criteria. The following is a list of the exclusion reasons: (1) the study was performed on other patients, except for renal patients; (2) the study was conducted in a country other than Iran; (3) the articles looked at risk factors or blood pressure complications. The full text of 218 articles was reviewed. Among them, 182 articles were excluded, because they were incomplete or their full text was not available. In the remaining 36 articles, 1 article was removed because of low quality. Finally, 35 appropriate articles were selected to enter the meta-analysis stage \[[Figure 1](#F1){ref-type="fig"}\].
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Quality evaluation {#sec2-4}
------------------

All studies that reported the prevalence of osteoporosis in Iranian elderly people entered the study. To assess the quality of the studies, STROBE (3) was used as the standard checklist. This checklist contains 22 items that cover different parts of a report (sampling, measurement of variables, study objectives, and statistical analysis). One point was given to each item, and some other items that were more important to us had more points. The STROBE checklist contains 22 sections that cover different parts of a report, and the maximum score of a report equals 44, so that a score of 1--15 indicates poor quality, 16--30 shows average quality, and 31--44 is considered to be excellent. Articles with a total score of less than 16 were excluded from the meta-analysis.

Data extraction {#sec2-5}
---------------

To reduce reporting bias and error in data collection, two researchers independently extracted data from articles and entered the extracted data into a checklist containing the following items: first author\'s name, study title, sample size, year and place of study, prevalence of hypertension in renal patients based on sex, prevalence of systolic and diastolic hypertension, prevalence of diabetes, Type of disease, age, etc.

Statistical analysis {#sec2-6}
--------------------

To analyze and combine the results of various studies, the prevalence of hypertension in renal patients in each study was considered as a binomial probability distribution and its variance was calculated by binomial distribution. The heterogeneity of studies was measured using the Q test and I square (I^2^) index. Due to the heterogeneity of the studies, the random effects model was used to combine the results of the studies. The data were analyzed using STATA Ver. 11, and the significance level of the test was considered as 0.05.

Meta-regression was used to investigate the relationship between the prevalence of hypertension in renal patients and the sample size and year of research. Sensitivity analysis was used to determine the effect of removing each study on the final meta-analysis.

Results {#sec1-3}
=======

Summary of how to enter the articles into the meta-analysis process {#sec2-7}
-------------------------------------------------------------------

In 35 articles with a sample size of 39,621 people, the prevalence of hypertension in Iranian renal patients was 35% (95% CI: 29%--41%). The lowest and highest prevalence of hypertension were 9% in Brahimi\'s study\[[@ref50]\] and 86% in Fazelzadeh\'s study,\[[@ref51]\] respectively. Considering the heterogeneity of studies, the confidence interval (CI) for each study based on the random effects model is presented in [Diagram 1](#F2){ref-type="fig"}. The characteristics of the reviewed articles are presented in [Table 1](#T1){ref-type="table"}.

![Flowchart of studies to the systematic review and meta-analysis](IJPVM-10-124-g002){#F2}

###### 

Characteristics of Studies Qualified for Systematic Review and Meta-Analysis

  Author                            Age mean (SD)   Year of study   City of study                                Type of disease                   Sample size   Prevalence of hypertension (%)
  --------------------------------- --------------- --------------- -------------------------------------------- --------------------------------- ------------- --------------------------------
  \[[@ref52]\]Bashardoost           53 (16.7)       2006            Ardebil                                      Hemodialysis Patients             80            64.9
  \[[@ref53]\]Hasan Zamani          48 (18.03)      2011            Mashhad                                      Hemodialysis Patients             66            22.7
  \[[@ref54]\]Pourmand              39.3            2015            Tehran                                       Kidney transplantation patients   400           26.3
  \[[@ref55]\]Basiratnia            17.4            2011            Shiraz                                       Kidney transplantation patients   66            25.7
  \[[@ref56]\]Shamsa                35.26           2003-2004       Mashhad                                      Kidney transplantation patients   15            40
  \[[@ref51]\]Fazel zadeh           45              1988-1992       Shiraz                                       Kidney transplantation patients   500           86
  \[[@ref57]\]Houli saz             40.26           2006            Tehran                                       Kidney transplantation patients   119           63
  \[[@ref58]\]Nikoubakht            40.45           2001-2002       Tehran                                       Kidney transplantation patients   119           50
  \[[@ref59]\]Noushad               48              2003-2005       Tabriz                                       Kidney transplantation patients   50            26
  \[[@ref60]\]Rostami               40.7            2006-2009       Tehran                                       Kidney transplantation patients   804           58.2
  \[[@ref61]\]Pak fetrat            38.5            2000-2001       Shiraz                                       Kidney transplantation patients   1354          11.6
  \[[@ref62]\]Rezaei ghalehchi      25-70           2013            Ardebil                                      Hemodialysis Patients             100           38.2
  \[[@ref63]\]Noubakht haghighi     30.43           2005-2008       Iran                                         Donor nephrectomies               1549          \-
  \[[@ref64]\]Rouhani               61.3            2012            Tehran                                       Hemodialysis Patients             163           49.1
  \[[@ref65]\]Najafi                46.6            2001-2009       Iran                                         peritoneal dialysis               2302          24.4
  \[[@ref50]\]Barahimi              \>30            2011            Shahreza                                     Chronic kidney disease            11720         9
  \[[@ref66]\]Gheisari              11.01           2001-2011       Esfahan                                      Chronic kidney disease            268           55
  \[[@ref67]\]Jalal zadeh           56.6            2009-2010       Zanjan                                       Hemodialysis Patients             80            68.8
  \[[@ref68]\]Neamati               62              2006            Tehran, Ahvaz, Kermanshah, Mashhad, shiraz   Hemodialysis Patients             337           23.7
  \[[@ref69]\]Safari nezhad         \>14            2002-2005       Iran                                         Chronic kidney disease            16354         17.3
  \[[@ref70]\]Ayazi                 51.2            2002-2003       Tehran                                       peritoneal dialysis               21            38
  \[[@ref71]\]Nakhjavani            32-89           2001-2002       Tehran                                       Hemodialysis Patients             620           82.5
  \[[@ref72]\]Barzin                49              1998            Sari                                         Hemodialysis Patients             41            17
  \[[@ref73]\]Monfarad                              2001            Gilan                                        Hemodialysis Patients             414           17
  \[[@ref74]\]Shasti                62.2 (13.7)     2010            Tehran                                       Hemodialysis Patients             100           26.1
  \[[@ref75]\]Raeisi far            51.48           2005            Abadan                                       Hemodialysis Patients             59            40.4
  \[[@ref76]\]Ghafourifard          48.6 (19)       2008            Esfahan                                      Hemodialysis Patients             26            11.5
  \[[@ref77]\]Heidari               47              1998            Mazandaran                                   Hemodialysis Patients             353           24.6
  \[[@ref78]\]Mogharab              56-65           2007            Birjand                                      Hemodialysis Patients             40            12.5
  \[[@ref79]\]Eslami amirabadi      50.4 (15.2)     2014            Tehran                                       Hemodialysis Patients             189           23.3
  \[[@ref80]\]Rahimian              56.7            2005            Yazd                                         Hemodialysis Patients             60            12
  \[[@ref81]\]Ghorbani Moghaddam1   55.7 (15.63)    2014            Bushehr                                      Hemodialysis Patients             93            34.2
  \[[@ref82]\]Hadian                53.2 (16.4)     2011            Lorestan                                     Hemodialysis Patients             318           38.1
  \[[@ref83]\]Rezaein langroodi     56-65           2009            Hamedan                                      Hemodialysis Patients             455           22.1
  \[[@ref84]\]KhademVatan           55 (17.7)       2014            Orumie                                       Hemodialysis Patients             386           35.5

The prevalence of hypertension in women with renal disease was 25% (95% CI: 16%--35%) and in men was 18% (95% CI: 15%--22%). In addition, the prevalence of systolic hypertension in renal patients was 5% (95% CI: 0%--13%), the prevalence of diastolic hypertension was 26% (95% CI: 0%--77%), and the prevalence of diabetes was 23% (95% CI: 17%--29%). The prevalence of hypertension in women with renal disease is 7% higher than men \[[Table 2](#T2){ref-type="table"}\].

###### 

Prevalence of hypertension in renal patients in the studied subgroups

  Subgroups              Number of study                   Prevalence (95% CI)   *P*          *I*^2^ (%)   
  ---------------------- --------------------------------- --------------------- ------------ ------------ ------
  Sex                    Total                             34                    35 (29-41)   *P*\<0.001   99.5
                         Women                             3                     25 (16-35)   *P*\<0.001   91.7
                         Men                               3                     18 (15-22)   0.103        56.1
  Type of hypertension   Systolic                          3                     5 (0-13)     *P*\<0.001   99.2
  Diastolic              3                                 26 (0-77)             *P*\<0.001   100          
  Type of disease        Hemodialysis Patients             20                    34 (23-45)   *P*\<0.001   98.4
                         Kidney transplantation patients   9                     43 (19-67)   *P*\<0.001   99.6
                         Chronic kidney disease            3                     26 (17-34)   *P*\<0.001   99.7
                         Peritoneal dialysis               2                     27 (16-38)   0.201        38.9
  Age (Year)             \<30                              2                     41 (12-69)   *P*\<0.001   95.6
                         30-39                             3                     22 (9-36)    *P*\<0.001   95.3
                         40-49                             10                    39 (20-57)   *P*\<0.001   99.4
                         50-59                             11                    35 (26-44)   *P*\<0.001   94.0
                         60-70                             3                     32 (16-48)   *P*\<0.001   93.9
  Region                 North                             14                    42 (28-55)   *P*\<0.001   98.7
                         South                             2                     37 (29-44)   0.442        0
                         Center                            7                     30 (10-50)   *P*\<0.001   99.8
                         West                              5                     38 (25-50)   *P*\<0.001   95.3
                         East                              3                     21 (9-33)    0.091        58.4

In an analysis based on the type of renal disease, we found that the prevalence of hypertension in hemodialysis patients was 34% (95% CI: 23%--45%) in 20 reviewed studies. In nine other studies performed on renal transplant patients, the prevalence of hypertension was 43% (95% CI: 19%--67%). Two studies were also performed on peritoneal dialysis patients with a hypertension prevalence of 27% (95% CI: 16%--38%). The three last studies were conducted on chronic renal failure patients and we found that the prevalence of hypertension was 26% (95% CI: 17%--34%). The prevalence of hypertension in renal transplant patients is higher than that of hemodialysis, peritoneal, and chronic kidney dialysis patients \[[Table 2](#T2){ref-type="table"}\].

In an analysis performed based on the age group, the prevalence of hypertension was 41% (95% CI: 12%--69%) among 1--29-year-old renal patients, 22% (95% CI: 9%--36%) among 30--39-year-old patients, 39% (95% CI: 20%--57%) among 40--49-year-old renal patients, 35% (95% CI: 26%--44%) among 50--59-year-old renal patients, and 32% (95% CI: 16%--48%) among 60--70-year-old renal patients. Moreover, 1--29-year-old renal patients are more likely to have hypertension compared with other patients; however, given the varying number of studies in any age group, we cannot say with certainty \[[Table 2](#T2){ref-type="table"}\].

The prevalence of hypertension in renal patients in the north of Iran was 42% (95% CI: 28%--55%), in the south was 37% (95% CI: 29%--44%), in the center was 30% (95% CI: 10%--50%), and in the west was 38% (95% CI: 25%--50%). Renal patients in the north of Iran suffer more from high blood pressure compared with other regions of Iran \[[Table 2](#T2){ref-type="table"}\].

In sensitivity analysis, we find that the prevalence of hypertension in renal patients in Iran was reduced to 33.65% (95% CI: 28.55%--38.75%) by removing the study of Fazelzadeh\[[@ref20]\] and increased to 36.16% (95% CI: 28.58%--43.77%) after removing Brahimi\'s study,\[[@ref19]\] and these two studies are the most effective studies in the final meta-analysis \[[Figure 2](#F3){ref-type="fig"}\].
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Discussion {#sec1-4}
==========

In 35 reviewed studies with a sample of 39,621 subjects, the prevalence of hypertension in renal patients was 35% (95% CI: 29%--41%) (25% in women and 18% in men). The prevalence of systolic hypertension in renal patients was 5%, diastolic hypertension 26%, and diabetes 23%. The prevalence of hypertension in hemodialysis patients was 34%, 27% in peritoneal dialysis, 43% in kidney transplantation, and 26% in chronic renal failure. In addition, meta-regression showed that the prevalence of hypertension in renal patients did not significantly decrease during the years 1988--2017.

According to the initial care system surveys of noncommunicable disease risk factors in Iran in 2005, the prevalence of hypertension in individuals aged 15--64 was 17.1%.\[[@ref19][@ref20]\] In a general study, the prevalence of hypertension was 11% in Isfahan, 17% in Chaharmahal and Bakhtiari, 11.6% in Gilan, 17.5% in Zanjan, 6.25% in Kermanshah, and 18.9% in Arak.\[[@ref85]\] In the study of Bashardost *et al*., 44.9% of hemodialysis patients had high blood pressure.\[[@ref86]\] In a study on renal transplant patients, Rostami *et al*. found that the prevalence of hypertension was 58.2%.\[[@ref60]\] In another study by Rezaei Ghalechi to analyze depression in hemodialysis patients, the prevalence of hypertension and diabetes was 38.2% and 34.2%, respectively.\[[@ref62]\] The prevalence of hypertension was estimated to be 17.3% in a study conducted in Iran in 2002--2005 to investigate the risk factors associated with chronic kidney disease.\[[@ref69]\] In the study of Malekmakan *et al*., the most common causes of chronic renal failure in hemodialysis patients in Fars province were hypertension and diabetes.\[[@ref87]\] In a study entitled "A 17-year history of peritoneal dialysis in Iran," which was conducted on 2302 people, the prevalence of high blood pressure in these patients was 24.4%.\[[@ref65]\] Due to the differences in the results of studies on the prevalence of high blood pressure in renal patients, this study was conducted through systematic review and meta-analysis.

In 35 articles with a sample size of 39,621 individuals, performed from 1988 to 2017, 34 articles outlined the prevalence of high blood pressure in renal patients, and the prevalence of hypertension in renal patients was estimated to be 35% (95% CI: 29%--41%) (25% in women and 18% in men). The prevalence of systolic hypertension in renal patients was 5%, diastolic hypertension was 26%, and diabetes was 23%.

Meta-regression showed that there was no significant relationship between the prevalence of hypertension in renal patients and the number of research samples (*P* = 0.128), that is, with an increase in the number of samples, the prevalence of hypertension in renal patients decreased, but this was not statistically significant \[[Figure 3](#F4){ref-type="fig"}\]. There was no significant relationship between the prevalence of hypertension in renal patients and the year of study (*P* = 0.102). During the years 1988--2017, the prevalence of hypertension in renal patients in Iran decreased but was not statistically significant \[[Figure 4](#F5){ref-type="fig"}\]. In Figures [5](#F6){ref-type="fig"} and [6](#F7){ref-type="fig"}, we see that the effect of publication bias is not statistically significant.
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![Relationship between the prevalence of hypertension in renal patients in Iran and the year of research using meta-regression](IJPVM-10-124-g005){#F5}
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![Beggs test and Eggers test to examine the significance of bias](IJPVM-10-124-g007){#F7}

In the study of Familoni *et al*., 53.2% of the subjects referred to hypertension as one of the causes of brain attack, renal failure, and cardiac failure.\[[@ref88]\] In a study on patients in developed countries, 11.1% of the cause of chronic kidney disease was diabetes and 10.6% was high blood pressure.\[[@ref89]\] According to studies in the United States, the most common causes of kidney failure are diabetes (50%), and both diabetes and high blood pressure (50--80%).\[[@ref90]\] In a study in Pakistan in 1998--2001, high blood pressure (19.45%) and diabetes (19.67%) were identified as the most important causes of kidney failure.\[[@ref91]\] In a study in Australia in 1997, hypertension (12%) was the most common cause of chronic renal failure.\[[@ref92]\] In another study in Japan, this was reported as 6.2%.\[[@ref93]\] In a Saudi study on renal patients, the prevalence of hypertension was reported to be 22.1%.\[[@ref94]\]

Limitations of the study {#sec2-8}
------------------------

Lack of uniform distribution of studies in different regions of Iran, different age groups, and different genders. Failure to report hypertension accurately in some studies.

Conclusions {#sec1-5}
===========

The prevalence of hypertension in women with kidney disease is higher than men, and patients with kidney transplantation are at higher risk of hypertension than other renal patients. The prevalence of diastolic hypertension in renal patients is about five times higher than systolic blood pressure.
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